In a report released today, Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €153.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dylan Van Haaften’s rating is based on several key considerations. Despite some challenges, Merck KGaA’s recent quarterly results were in line with expectations, particularly in terms of top-line revenue and EBITDA. The company has shown encouraging progress in its Life Sciences Process Solutions segment, which experienced strong organic growth driven by a recovery in pharmaceutical production demand.
While there are some headwinds, such as foreign exchange impacts and tariff uncertainties, the company’s guidance adjustments reflect a cautious but strategic approach to navigating these challenges. The Healthcare segment also demonstrated positive growth, and the Electronics division, although facing some profitability concerns, showed modest growth due to AI-driven demand. These factors, combined with a favorable upside to the price target, underpin the Buy rating given by Dylan Van Haaften.
In another report released on May 12, Barclays also maintained a Buy rating on the stock with a €160.00 price target.